Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial

Data Presented at ASRS Confirm Previous Phase III Findings and Microplasmin's Potential to Transform the Treatment of Retinal Disorders

LEUVEN, Belgium, September 1, 2010 – ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical
company focused on the discovery and development of innovative treatments for
eye disease, vascular disease and cancer announces that its second Phase III
trial evaluating microplasmin [...]

Amsterdam Molecular Therapeutics Reports Half-Year Results 2010

AMSTERDAM, The Netherlands, August 31, 2010 – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field
of human gene therapy, today reported its results for the first half year of
2010.

Highlights

– Glybera(R):
– EMA initiated MAA review in 01/2010
– Approval [...]

InSightec Treats First Prostate Cancer Patients in Clinical Trials

ExAblate(R) MR Guided Focused Ultrasound System is Being Used for the First Time for Non-invasive Treatment of Prostate Cancer

TIRAT CARMEL, Israel, August 31, 2010 – InSightec Ltd., the global leader in MR guided focused ultrasound
technology and the only company to receive FDA approval for its ExAblate(R)
system for treating uterine fibroids, announced today that its [...]

PharmaVentures Appoints Paul Phull as Senior Director

New Business Development Expert Brings More Than 20 Years of Industry M&A and Licensing Experience to Strengthen Pharmaventures' Corporate Advisory Services to its Clients

OXFORD, England, August 31, 2010 – PharmaVentures Ltd (www.pharmaventures.com) ("PharmaVentures")
today announced that Paul Phull has joined the company as Senior Director.
With more than 24 years of senior level commercial, business/corporate
development and [...]

Serono Symposia International Foundation (SSIF) Launches a New Web Site Dedicated to Medical Education on Phenylketonuria (PKU)

A New Tool is Targeted to Specialists in PKU, Offering an Advanced Educational Pathway Consisting of CME Accredited e-Learning Modules

ROME, August 31, 2010 – PKU specialists around the world can now count on a brand-new,
authoritative website entirely dedicated to this rare genetic disorder, which
affects one out of every 10,000 to 20,000 live births worldwide.

[...]

Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products

LONDON, August 31, 2010 – Following a recent analysis of the medical imaging devices market, Frost
& Sullivan presented Lodox Systems (Pty) Ltd (Lodox) with the "2010 South
African Medical Imaging Product Quality Leadership Award". Statscan, Lodox's
digital x-ray product, stunned the market with its ability to produce clear,
diagnostic, whole-body x-ray pictures in just 13 seconds.

[...]

ASP GLOSAIR(TM) Decontamination Technology Undertakes Deep Clean at Royal Liverpool Hospital to Promote Better Patient Care

LONDON, August 31, 2010 – Advanced Sterilization Products (ASP) announced today a partnership with
the Royal Liverpool University Hospital to strengthen their infection
prevention efforts and promote better patient care by utilizing ASP's proven
GLOSAIR(TM) area decontamination technology.

As part of a larger refurbishment project, Royal Liverpool University
Hospital has appointed ASP to perform their [...]

OrthoAccel Technologies Announces Full-Market Release of AcceleDent, a New Technology to Shorten Treatment Time in Braces

HOUSTON, August 31, 2010 – OrthoAccel Technologies, Inc. (www.acceledent.co.uk/home)
announced this week that following a successful limited market release of
AcceleDent last October it will be initiating a full-market release
throughout the United Kingdom this coming September. Availability of
AcceleDent (www.acceledent.co.uk), which is a regulated medical device
and only available to dental professionals to prescribe to their patients,
will be [...]

New Report World Dermatology Market (Drugs, Therapeutic Segments and Disorders) (2010 to 2015) Published By MarketsandMarkets

DALLAS, August 31, 2010 – More than 10,00,000 new cases of skin nonmelanoma cancer has been
reported for the current year only in U.S. This enhanced the market for anti
skin cancer drugs and therapies within the dermatology market. Dermatology
continues to remain one of the promising sectors within the pharmaceutical
market due to recent drug developments in [...]

CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up

The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent's Outstanding Efficacy and Safety

STOCKHOLM, August 31, 2010 – Cordis Corporation, a worldwide leader in the development and manufacture
of interventional vascular technology, announced today at European Society of
Cardiology in Stockholm that the results of follow-up tests undertaken [...]

Glenmark Announces the Discovery of a Novel Chemical Entity ‘GRC 17536′, a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally

With This Announcement, Glenmark has Clearly Reaffirmed its Position Globally as the Leader in the TRP Space

MUMBAI, India, August 31, 2010 – Glenmark Pharmaceuticals today announced the discovery of a
Novel Chemical Entity(NCE) 'GRC 17536'. The new NCE program is targeting
TRPA1 receptor antagonists for pain and respiratory disorders. TRPA1 belongs
to Transient Receptor Potential (TRP) family [...]

Henry Schein Provides Health Care Products for Relief After Flooding in Pakistan

Company establishes matching relief fund for Pakistan through Henry Schein Cares Foundation

MELVILLE, New York, August 31, 2010 – Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of health care
products and services to office-based practitioners, is working with its non-
governmental organization (NGO) partners – Direct Relief, International
Medical Corps, Americares, and Heart to Heart – to [...]

The Top 10 Cardiovascular Device Companies: Market Trends, Growth Strategies, and SWOT Analyses Now Available at ReportsandReports

DALLAS, Texas, August 31, 2010 – ReportsandReports announces it will carry the The Top 10 Cardiovascular
Device Companies: Market trends, growth strategies, and SWOT analyses Market
Research Report in its store.

Browse the complete Report on:
www.reportsandreports.com/market-reports/the-top-10-cardiovascular-dev
ice-companies-market-trends-growth/
Search More Then 45000 Market Research Reports at ReportsandReports
(www.reportsandreports.com/)
The cardiovascular [...]

ScinoPharm to Invest in Tanvex Biologics

TAINAN, Taiwan, August 31, 2010 – ScinoPharm, a leading active pharmaceutical ingredient (API) developer
and manufacturer headquartered in Taiwan, today announced an investment into
Tanvex Biologics, Inc., a United States company registered in the State of
Delaware. ScinoPharm's investment was in the form of tangible assets,
intellectual properties, as well as cash.

Tanvex specializes in [...]

Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients

Study meets primary endpoint of reducing lactate levels in trauma patients treated with MP4OX

SAN DIEGO, August 31, 2010 – Sangart, Inc., today announced positive results from its Phase IIa
proof-of-concept study of MP4OX (oxygenated pegylated hemoglobin) in severely
injured trauma patients with hemorrhagic shock causing lactic acidosis. The
study demonstrated that MP4OX, when given in addition to [...]

New Data Supports Valdoxan’s(R) Unique Clinical Signature

AMSTERDAM, August 31, 2010 – Valdoxan(R)/Thymanax(R) (agomelatine) is more efficacious than
both conventional selective serotonin reuptake inhibitor (SSRI) and serotonin
noradrenaline reuptake inhibitor (SNRI) antidepressants, according to new
data presented today at the 23rd European College of Neuropsychopharmacology
(ECNP) Congress.

To view the Multimedia News Release, please click:
multivu.prnewswire.com/mnr/prne/valdoxan/44196/
[...]

Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients

First Results From the TEMSO Phase III Trial to be Presented During the ECTRIMS Congress in October 2010

PARIS, August 30, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today
that the investigational once-daily oral drug teriflunomide significantly
reduced annualized relapse rate (ARR) at 2 years versus placebo in patients
with relapsing multiple sclerosis (RMS), thus achieving [...]

ATOLL Study Results With Intravenous Enoxaparin in Acute Heart Attack Managed with Urgent Angioplasty

Composite Primary Endpoint: Risk Reduction of 17% (Non-Statistically Significant ) in Death, Complication of Myocardial Infraction, Procedure Failure or Major Bleeding (p=0.07)

PARIS, August 30, 2010 – Pitie-Salpetriere Hospital, Paris, France, August 30th 2010.
The international ATOLL study sponsored by the Assistance Publique – Hopitaux
de Paris showed that enoxaparin reduced the composite of death, complication
of myocardial [...]

From the Laboratory to the Reality of Daily Life

Picture is available via epa european pressphoto agency and can be downloaded free of charge at: https://www.presseportal.de/pm/32079

DUDERSTADT, Germany, August 30, 2010 – Christian Kandlbauer, who lost both of his arms in a high
voltage accident, uses a unique development which until recently sounded
almost like science fiction: An arm prosthesis, the first of its kind in [...]

Elsevier Introduces SciVerse, an Innovative Platform for Accelerating Science

AMSTERDAM, August 30, 2010 -

– Integrates ScienceDirect, Scopus and Targeted Web Content;
Offers New Search and Discovery Applications -

– Opening APIs to Encourage Development of Customized Solutions -

Elsevier, (www.elsevier.com/) a world-leading publisher of
scientific, technical and medical information [...]